Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||NT-I7 + Radiotherapy + Temozolomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|NT-I7||GX-I7|rhIL-7-hyFc|IL-7-hyFc|Efineptakin alfa|Hyleukin||NT-I7 is a fusion protein comprised of a recombinant interleukin-7 (IL-7) linked to a hybrid immunoglobulin Fc region, which potentially has increased stability and enhances anti-tumor immune response (Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516).|
|Temozolomide||Temodar||Methazolastone||Chemotherapy - Alkylating 14||Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03687957||Phase Ib/II||Radiotherapy + Temozolomide NT-I7 + Radiotherapy + Temozolomide||rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-lymphopenic Gliomas Following Radiation and Temzolomide||Recruiting|